A 56-year old woman with a background of cardiovascular disease has ongoing dyslipidaemia despite treatment with a variety of lipid lowering therapies.

After treatment with both atorvastatin 80mg and ezetimibe 10mg, her non-HDL cholesterol remained >2.5mmol/L.

She was subsequently referred to lipid management clinic for consideration of treatment escalation.

Injectable lipid lowering therapy may be considered for patients with non-HDL-C levels greater than what?

This MedShr educational programme has been funded by an arm’s length sponsorship by Novartis Pharmaceuticals UK Limited (“Novartis”). Novartis has had no input in development of the content or involvement in the delivery or execution of the educational programme. Anonymized data may be shared with Novartis.